<!DOCTYPE html SYSTEM "about:legacy-compat">
<html xmlns:ns0="http://www.w3.org/2001/XInclude" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
    <title>DC Code - Subchapter III. Substitution of Therapeutically Equivalent Drugs.</title>
    <meta property="st:title" content="Subchapter III. Substitution of Therapeutically Equivalent Drugs."/>
    <meta name="description" content="A simple, free browser for the Washington, DC Code"/>
    <meta name="viewport" content="width=device-width"/>
    <link href="https://fonts.googleapis.com/css?family=Open+Sans:400italic,700italic,400,700" rel="stylesheet" type="text/css"/>
    <link rel="stylesheet" type="text/css" href="/css/reset.css" media="screen"/>
    <link rel="stylesheet" type="text/css" href="/css/site.css" media="screen"/>
    <link rel="stylesheet" type="text/css" href="/css/body.css" media="screen"/>
    <link rel="stylesheet" type="text/css" href="/css/print.css" media="print"/>
    <link rel="stylesheet" type="text/css" href="/css/icons/style.css" media="screen"/>
    <script type="text/javascript">
            var _paq = _paq || [];
            _paq.push(['trackPageView']);
            _paq.push(['enableLinkTracking']);
            (function() {
              var u="//analytics.code.dccouncil.us/";
              _paq.push(['setTrackerUrl', u+'piwik.php']);
              _paq.push(['setSiteId', 1]);
              var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0];
              g.type='text/javascript'; g.async=true; g.defer=true; g.src=u+'piwik.js'; s.parentNode.insertBefore(g,s);
            })();

          window.searchHost = 'https://search.code.dccouncil.us';
          window.queryUrl = '/v1/search';
          </script>
    <noscript>
      <p>
        <img src="//analytics.code.dccouncil.us/piwik.php?idsite=1" style="border:0;" alt=""/>
      </p>
    </noscript>
  </head>
  <body>
    <header>
      <div class="container">
        <div class="right no-print search" id="search"> </div>
        <h1 id="sitename">
          <a href="/dc/council/code/">Code of the District of Columbia</a>
        </h1>
      </div>
    </header>
    <div class="main container">
      <div class="clearfix" style="width: 100%;">
        <div id="sidebar" class="col4 quiet">
          <h2>You Are Here</h2>
          <ul class="ancestors">
            <li>↪ <a href="/">D.C. Law Library</a></li>
            <li>↪ <a href="/dc/council/code/">Code of the District of Columbia</a></li>
            <li>↪ <a href="/dc/council/code/titles/48/">Title 48. Foods and Drugs.</a></li>
            <li>↪ <a href="/dc/council/code/titles/48/chapters/8/">Chapter 8. Prescription Drug Price Information.</a></li>
            <li>↪ Subchapter III. Substitution of Therapeutically Equivalent Drugs.</li>
          </ul>
          <h2>Previous</h2>
          <p>
            <a class="internal-link" href="/dc/council/code/titles/48/chapters/8/subchapters/II/">Subchapter II. Advertising.</a>
          </p>
          <h2>Next</h2>
          <p>
            <a class="internal-link" href="/dc/council/code/titles/48/chapters/8/subchapters/IV/">Subchapter IV. Enforcement.</a>
          </p>
          <h2>Publication Information</h2>
          <h3>Current through January 09, 2016</h3>
          <dl id="recency">
          <dt>Last codified D.C. Law:</dt>
          <dd>
            Law 21-46 effective January 09, 2016</dd>
          <dt>Last codified Emergency Law:</dt>
          <dd>
            Act 21-240 effective December 21, 2015</dd>
          <dt>Last codified Federal Law:</dt>
          <dd>
            Public Law 114-95 approved December 10, 2015</dd>
        </dl>
          <div class="cta">
            <p>
              <a href="mailto:code@dccouncil.us?subject=[ERROR]+/dc/council/code/titles/48/chapters/8/subchapters/III/">Report Error</a>
            </p>
            <p>
              <a href="mailto:code@dccouncil.us?subject=[FEEDBACK]+/dc/council/code/titles/48/chapters/8/subchapters/III/">Website Feedback</a>
            </p>
            <p>We cannot respond to questions regarding the law.</p>
          </div>
        </div>
        <div class="col8 body">
          <h1>Subchapter III. Substitution of Therapeutically Equivalent Drugs.</h1>
          <div class="toc">
            <div class="line-group toc">
              <div class="line child-link " style="text-indent: 0em">
                <div>
                  <span class="title">
                    <a class="internal-link" href="/dc/council/code/sections/48-803.01.html">§ 48–803.01. Generically equivalent drug formulary; therapeutic interchange list.</a>
                  </span>
                </div>
              </div>
              <div class="line child-link " style="text-indent: 0em">
                <div>
                  <span class="title">
                    <a class="internal-link" href="/dc/council/code/sections/48-803.02.html">§ 48–803.02. Dispensing of generically equivalent drug products.</a>
                  </span>
                </div>
              </div>
              <div class="line child-link " style="text-indent: 0em">
                <div>
                  <span class="title">
                    <a class="internal-link" href="/dc/council/code/sections/48-803.03.html">§ 48–803.03. Dispensing of substitute drug products — conditions.</a>
                  </span>
                </div>
              </div>
              <div class="line child-link " style="text-indent: 0em">
                <div>
                  <span class="title">
                    <a class="internal-link" href="/dc/council/code/sections/48-803.03a.html">§ 48–803.03a. Dispensing of substitute drug products by pharmacists — notification of substitution.</a>
                  </span>
                </div>
              </div>
              <div class="line child-link " style="text-indent: 0em">
                <div>
                  <span class="title">
                    <a class="internal-link" href="/dc/council/code/sections/48-803.04.html">§ 48–803.04. Dispensation of equivalent products by pharmacists — Recording and labeling required.</a>
                  </span>
                </div>
              </div>
              <div class="line child-link " style="text-indent: 0em">
                <div>
                  <span class="title">
                    <a class="internal-link" href="/dc/council/code/sections/48-803.05.html">§ 48–803.05. Dispensation of equivalent products by pharmacists — Consideration as practice of medicine or evidence of negligence; failure of physician to specify specific brand.</a>
                  </span>
                </div>
              </div>
            </div>
          </div>
          <div class="content">
            <hr/>
            <div class="line heading heading-1" style="text-indent: 0em">
              <p>
                <span class="" style="">§ 48–803.01. Generically equivalent drug formulary; therapeutic interchange list.</span>
              </p>
            </div>
            <div>
                    <div class="line-group primary-content">
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(a)</span>
                          <span>The formulary of generically equivalent drug products for the District of Columbia shall be the chemical and generic drugs contained in the Food and Drug Administration publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” including all updates issued by the Food and Drug Administration (“Orange Book”).</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(b)</span>
                          <span>The Boards of Pharmacy and Medicine may jointly establish a therapeutic interchange list.</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(c)</span>
                          <span>If a therapeutic interchange list is established pursuant to subsection (b) of this section:</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 2.5em">
                        <p>
                          <span class="level-num">(1)</span>
                          <span>The Boards of Pharmacy and Medicine shall:</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 3.75em">
                        <p>
                          <span class="level-num">(A)</span>
                          <span>Revise or supplement the therapeutic interchange list as necessary;</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 3.75em">
                        <p>
                          <span class="level-num">(B)</span>
                          <span>Establish procedures to allow a prescriber to consent to the substitution of therapeutically equivalent drug products without prior approval based on the therapeutic interchange list; provided, that a prescriber be allowed to limit authorization to specific conditions or patients and that no prescriber be required for any reason to consent to participation in the therapeutic interchange list; and</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 3.75em">
                        <p>
                          <span class="level-num">(C)</span>
                          <span>Establish and maintain a database, searchable in real time, of those prescribers who have consented to use of the therapeutic interchange list, including any restrictions based on specific conditions or patients; and</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 2.5em">
                        <p>
                          <span class="level-num">(2)</span>
                          <span>The Department of Health shall distribute the therapeutic interchange list to all pharmacies licensed in the District and shall publish it regularly in the District of Columbia Register.</span>
                        </p>
                      </div>
                    </div>
                    <div class="line-group annotations">
                      <div class="line" style="text-indent: 1.5em">
      (<a class="internal-link" href="/dc/council/laws/1-81.html">Sept. 10, 1976, D.C. Law 1-81, title III, § 301, 23 DCR 2460</a>; <a class="internal-link" href="/dc/council/laws/1-114.html">Apr. 7, 1977, D.C. Law 1-114, § 4(a), 23 DCR 8743</a>; <a class="internal-link" href="/dc/council/laws/18-118.html">Mar. 11, 2010, D.C. Law 18-118, § 2(a), 57 DCR 901</a>.)
    </div>
                      <div class="line subheading">Prior Codifications</div>
                      <div class="line" style="text-indent: 1.5em">1981 Ed., § 33-731.</div>
                      <div class="line" style="text-indent: 1.5em">1973 Ed., § 33-831.</div>
                      <div class="line subheading">Effect of Amendments</div>
                      <div class="line" style="text-indent: 1.5em"><a class="internal-link" href="/dc/council/laws/18-118.html">D.C. Law 18-118</a> rewrote the section, which had read as follows: “The Department of Human Services shall publish a formulary of drug products, with the chemical or generic name of each, that are determined to be therapeutically equivalent to specified brand name drug products. The Department shall determine the contents of the formulary only after recommendations are made by a committee of 9 members appointed by the Director of that Department. The committee shall consist of one licensed physician and one licensed pharmacist employed by the Department, 2 licensed physicians and 3 licensed pharmacists in private practice in the District, and 2 pharmacologists on the faculty of a university in the District. The recommendations of the committee shall require concurrence of a majority of the members of the committee. The committee’s recommendations shall be published in the District of Columbia Register as proposed regulations of the Department. The Department’s determinations shall be made in accordance with §§ <a class="internal-link" href="/dc/council/code/sections/2-503.html">2-503</a>, <a class="internal-link" href="/dc/council/code/sections/2-504.html">2-504</a> and <a class="internal-link" href="/dc/council/code/sections/2-505.html">2-505</a> and published in the District of Columbia Register as final regulations. The committee shall review the published formulary annually, or whenever an amendment to it appears necessary. The committee shall publish its 1st recommendations no later than 8 months after April 7, 1977.”</div>
                    </div>
                  </div>
            <hr/>
            <div class="line heading heading-1" style="text-indent: 0em">
              <p>
                <span class="" style="">§ 48–803.02. Dispensing of generically equivalent drug products.</span>
              </p>
            </div>
            <div>
                    <div class="line-group primary-content">
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(a)</span>
                          <span class="level-num">(1)</span>
                          <span>When a pharmacist receives a prescription for a brand name drug, the pharmacist may dispense a generically equivalent drug product that is listed in the Orange Book; provided, that the pharmacist shall dispense a generically equivalent drug product if requested by the purchaser, except as provided in § <a class="internal-link" href="/dc/council/code/sections/48-803.03.html">48-803.03</a>.</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 2.5em">
                        <p>
                          <span class="level-num">(2)</span>
                          <span>If a generic substitution is made pursuant to this subsection, the pharmacist shall dispense the generically equivalent drug product in stock having the lowest cost to the person purchasing the drug product.</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(b)</span>
                          <span>When a pharmacist receives a prescription for a drug by generic name, the pharmacist shall dispense the listed product in stock that has the lowest cost to the person purchasing the drug product.</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(c)</span>
                          <span>Repealed.</span>
                        </p>
                      </div>
                    </div>
                    <div class="line-group annotations">
                      <div class="line" style="text-indent: 1.5em">
      (<a class="internal-link" href="/dc/council/laws/1-81.html">Sept. 10, 1976, D.C. Law 1-81, title III, § 302, 23 DCR 2460</a>; <a class="internal-link" href="/dc/council/laws/1-114.html">Apr. 7, 1977, D.C. Law 1-114, § 4(a), 23 DCR 8743</a>; <a class="internal-link" href="/dc/council/laws/18-118.html">Mar. 11, 2010, D.C. Law 18-118, § 2(b), 57 DCR 901</a>.)
    </div>
                      <div class="line subheading">Section References</div>
                      <div class="line" style="text-indent: 1.5em">This section is referenced in § <a class="internal-link" href="/dc/council/code/sections/48-803.03.html">48-803.03</a> and § <a class="internal-link" href="/dc/council/code/sections/48-803.05.html">48-803.05</a>.</div>
                      <div class="line subheading">Prior Codifications</div>
                      <div class="line" style="text-indent: 1.5em">1981 Ed., § 33-732.</div>
                      <div class="line" style="text-indent: 1.5em">1973 Ed., § 33-832.</div>
                      <div class="line subheading">Effect of Amendments</div>
                      <div class="line" style="text-indent: 1.5em"><a class="internal-link" href="/dc/council/laws/18-118.html">D.C. Law 18-118</a> rewrote the section.</div>
                    </div>
                  </div>
            <hr/>
            <div class="line heading heading-1" style="text-indent: 0em">
              <p>
                <span class="" style="">§ 48–803.03. Dispensing of substitute drug products — conditions.</span>
              </p>
            </div>
            <div>
                    <div class="line-group primary-content">
                      <div class="line" style="text-indent: 1.25em">A pharmacist shall not dispense a:</div>
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(1)</span>
                          <span>Substitute drug product if the person purchasing the drug product or the patient for whom it is intended indicates a preference for the drug product actually prescribed;</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(2)</span>
                          <span>Generically equivalent drug product pursuant to § <a class="internal-link" href="/dc/council/code/sections/48-803.02.html">48-803.02</a> if:</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 2.5em">
                        <p>
                          <span class="level-num">(A)</span>
                          <span>The prescriber writes on a prescription order, signed by the prescriber, in the prescriber’s own handwriting “dispense as written” or “D.A.W.” or a similar notation; provided, that checking or initialing a box preprinted or stamped on a prescription form shall not constitute an acceptable notation; or</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 2.5em">
                        <p>
                          <span class="level-num">(B)</span>
                          <span>The prescriber, by telephone, expressly indicates that the prescription is to be dispensed as communicated and this indication is noted in the pharmacist’s own handwriting in the manner provided in subparagraph (A) of this paragraph;</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(3)</span>
                          <span class="level-num">(A)</span>
                          <span>Therapeutically equivalent drug product unless:</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 3.75em">
                        <p>
                          <span class="level-num">(i)</span>
                          <span class="level-num">(I)</span>
                          <span>The pharmacist or pharmacist’s agent obtains prior approval from the prescriber or the prescriber’s agent before the therapeutically equivalent drug product can be dispensed; or</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 5em">
                        <p>
                          <span class="level-num">(II)</span>
                          <span>The therapeutically equivalent drug product is included on the therapeutic interchange list and the endorsing prescriber has given consent to the Boards of Pharmacy and Medicine to permit therapeutic interchange without prior approval;</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 3.75em">
                        <p>
                          <span class="level-num">(ii)</span>
                          <span>The person purchasing the drug product provides consent to the therapeutic interchange;</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 3.75em">
                        <p>
                          <span class="level-num">(iii)</span>
                          <span>The therapeutically equivalent drug product does not have a higher cost to the purchaser than the originally prescribed drug product; provided, that the pharmacist may dispense a more expensive therapeutically equivalent drug product if consent is provided by the purchaser; and</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 3.75em">
                        <p>
                          <span class="level-num">(iv)</span>
                          <span>The dispensing pharmacist, or pharmacist’s agent, has notified the prescriber or prescriber’s agent of the specific drug and dose dispensed.</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 2.5em">
                        <p>
                          <span class="level-num">(B)</span>
                          <span>A pharmacist shall not dispense a therapeutically equivalent drug product for a prescription refill of an antipsychotic, antidepressant, chemotherapy, antiretroviral, or immunosuppressive drug but shall dispense the drug as prescribed.</span>
                        </p>
                      </div>
                    </div>
                    <div class="line-group annotations">
                      <div class="line" style="text-indent: 1.5em">
      (<a class="internal-link" href="/dc/council/laws/1-81.html">Sept. 10, 1976, D.C. Law 1-81, title III, § 303, 23 DCR 2460</a>; <a class="internal-link" href="/dc/council/laws/1-114.html">Apr. 7, 1977, D.C. Law 1-114, § 4(a), 23 DCR 8743</a>; <a class="internal-link" href="/dc/council/laws/18-118.html">Mar. 11, 2010, D.C. Law 18-118, § 2(c), 57 DCR 901</a>.)
    </div>
                      <div class="line subheading">Section References</div>
                      <div class="line" style="text-indent: 1.5em">This section is referenced in § <a class="internal-link" href="/dc/council/code/sections/48-803.02.html">48-803.02</a>.</div>
                      <div class="line subheading">Prior Codifications</div>
                      <div class="line" style="text-indent: 1.5em">1981 Ed., § 33-733.</div>
                      <div class="line" style="text-indent: 1.5em">1973 Ed., § 33-833.</div>
                      <div class="line subheading">Effect of Amendments</div>
                      <div class="line" style="text-indent: 1.5em"><a class="internal-link" href="/dc/council/laws/18-118.html">D.C. Law 18-118</a> rewrote the section.</div>
                    </div>
                  </div>
            <hr/>
            <div class="line heading heading-1" style="text-indent: 0em">
              <p>
                <span class="" style="">§ 48–803.03a. Dispensing of substitute drug products by pharmacists — notification of substitution.</span>
              </p>
            </div>
            <div>
                    <div class="line-group primary-content">
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(a)</span>
                          <span>An individual shall be notified of a drug substitution and provided the right to refuse the substitution prior to purchase of the substitute drug product.</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(b)</span>
                          <span class="level-num">(1)</span>
                          <span>The Department of Health shall create and distribute to all pharmacies signs that state in block letters not less than one inch in height: “This pharmacy may substitute a less expensive drug product that is equivalent to the one prescribed by your health care practitioner unless you request otherwise.</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 2.5em">
                        <p>
                          <span class="level-num">(2)</span>
                          <span>Each pharmacy shall display the sign in a prominent place that has a clear and unobstructed public view at or near the place where prescriptions are dispensed.</span>
                        </p>
                      </div>
                    </div>
                    <div class="line-group annotations">
                      <div class="line" style="text-indent: 1.5em">
      (<a class="internal-link" href="/dc/council/laws/1-81.html">Sept. 10, 1976, D.C. Law 1-81, § 301</a>; <a class="internal-link" href="/dc/council/laws/18-118.html">as added Mar. 11, 2010, D.C. Law 18-118, § 2(d), 57 DCR 901</a>.)
    </div>
                    </div>
                  </div>
            <hr/>
            <div class="line heading heading-1" style="text-indent: 0em">
              <p>
                <span class="" style="">§ 48–803.04. Dispensation of equivalent products by pharmacists — Recording and labeling required.</span>
              </p>
            </div>
            <div>
                    <div class="line-group primary-content">
                      <div class="line" style="text-indent: 1.25em">When a drug is substituted under this subchapter, the pharmacist shall record on the prescription form the drug substituted by name and manufacturer, and retain the form for inspection by District officials. The pharmacist shall also label the prescription container with the name of the drug substituted, unless the prescribing physician writes “do not label,” or words of similar import, on the prescription, or, in communicating the prescription by telephone, orders that the container not be so labelled.</div>
                    </div>
                    <div class="line-group annotations">
                      <div class="line" style="text-indent: 1.5em">
      (<a class="internal-link" href="/dc/council/laws/1-81.html">Sept. 10, 1976, D.C. Law 1-81, title III, § 304, 23 DCR 2460</a>; <a class="internal-link" href="/dc/council/laws/18-118.html">Mar. 11, 2010, D.C. Law 18-118, § 2(e), 57 DCR 901</a>.)
    </div>
                      <div class="line subheading">Prior Codifications</div>
                      <div class="line" style="text-indent: 1.5em">1981 Ed., § 33-734.</div>
                      <div class="line" style="text-indent: 1.5em">1973 Ed., § 33-834.</div>
                      <div class="line subheading">Effect of Amendments</div>
                      <div class="line" style="text-indent: 1.5em"><a class="internal-link" href="/dc/council/laws/18-118.html">D.C. Law 18-118</a> substituted “this subchapter” for “§ <a class="internal-link" href="/dc/council/code/sections/48-803.02.html">48-803.02</a>”.</div>
                    </div>
                  </div>
            <hr/>
            <div class="line heading heading-1" style="text-indent: 0em">
              <p>
                <span class="" style="">§ 48–803.05. Dispensation of equivalent products by pharmacists — Consideration as practice of medicine or evidence of negligence; failure of physician to specify specific brand.</span>
              </p>
            </div>
            <div>
                    <div class="line-group primary-content">
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(a)</span>
                          <span>The substitution of drugs by a licensed pharmacist under this subchapter shall not constitute the practice of medicine. Nothing in this subchapter shall be construed as authorizing a pharmacist to prescribe any drug or medication.</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(b)</span>
                          <span>Substitution of drugs made in accordance with § <a class="internal-link" href="/dc/council/code/sections/48-803.02.html">48-803.02</a> shall not constitute evidence of negligence or improper pharmacy practice if the substitution was made within reasonable and prudent pharmacy practice or if the prescribed and substituted drugs were generically equivalent drug products drugs [sic] as determined under this chapter.[sic]</span>
                        </p>
                      </div>
                      <div class="line" style="text-indent: 1.25em">[sic]</div>
                      <div class="line" style="text-indent: 1.25em">
                        <p>
                          <span class="level-num">(c)</span>
                          <span>Failure of a licensed physician to specify that a specific brand is necessary for the particular patient shall not constitute evidence of negligence unless the physician had reasonable cause to believe that the health of the patient required the use of that brand and no other.</span>
                        </p>
                      </div>
                    </div>
                    <div class="line-group annotations">
                      <div class="line" style="text-indent: 1.5em">
      (<a class="internal-link" href="/dc/council/laws/1-81.html">Sept. 10, 1976, D.C. Law 1-81, title III, § 305, 23 DCR 2460</a>; <a class="internal-link" href="/dc/council/laws/1-114.html">Apr. 7, 1977, D.C. Law 1-114, § 4(b), 23 DCR 8743</a>; <a class="internal-link" href="/dc/council/laws/18-118.html">Mar. 11, 2010, D.C. Law 18-118, § 2(f), 57 DCR 901</a>.)
    </div>
                      <div class="line subheading">Prior Codifications</div>
                      <div class="line" style="text-indent: 1.5em">1981 Ed., § 33-735.</div>
                      <div class="line" style="text-indent: 1.5em">1973 Ed., § 33-835.</div>
                      <div class="line subheading">Effect of Amendments</div>
                      <div class="line" style="text-indent: 1.5em"><a class="internal-link" href="/dc/council/laws/18-118.html">D.C. Law 18-118</a> rewrote subsec. (a); and, in subsec. (b), substituted “generically equivalent drug products” for “therapeutically equivalent”. Prior to amendment, subsec. (a) read as follows: “(a) The substitution of therapeutically equivalent drugs by a licensed pharmacist under § <a class="internal-link" href="/dc/council/code/sections/48-803.02.html">48-803.02</a> shall not constitute the practice of medicine.”</div>
                    </div>
                  </div>
            <hr/>
          </div>
        </div>
      </div>
    </div>
    <footer>
      <div class="container center">
        <p>The codes and laws on this website are in the public domain.</p>
        <p>
              Please do not scrape. Instead, bulk download the <a href="https://github.com/dccouncil/dc-law-html">HTML</a> or <a href="https://github.com/dccouncil/dc-law-xml">XML</a>.
            </p>
      </div>
    </footer>
    <script type="text/javascript" src="/js/search.js"> </script>
  </body>
</html>
